Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Mann J. F. E., Schmieder R. E., McQueen M., Dyal L., Schumacher H., Pogue J., ...Daha Fazla

LANCET, cilt.372, sa.9638, ss.547-553, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 372 Sayı: 9638
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/s0140-6736(08)61236-2
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.547-553
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage.